Not Tagged
Not Tagged
['breast', 'nsclc', 'sclc']
clinical responses were observed in patients treated w/ df1001 at doses of 1.6 mg/kg or greater. 5 patients experienced partial response &amp; 15 patients had stable disease with monotherapy. responses were observed in both her2 high &amp; her2 low breast cancer &amp; nsclc patients #asco23
We are a clinical-stage company developing drugs targeting natural killer cells & other cells of the innate immune system, to eliminate cancer & other diseases.